Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study
Patients who have been diagnosed with CKD based on Clinical Practice Guideline
During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg/m2
The sUA levels \> 420 μmol/L (7.0 mg/dL)
You may not be if
History of renal transplantation
The 24-hour urinary protein ≥ 3.5 g/day
Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase \> 3 times the upper limit of normal value (ULN)
Subjects with mental disorders who are unable to communicate normally with the investigator
Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study
The investigator judged that the subject was not suitable for participation in this study
Clareo Health | Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
